Loading
A phase 1/2 trial of SCTB41 in advanced solid tumours, run by Sinocelltech Ltd., now recruiting.
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. is a phase 1/2 interventional study registered as NCT06600022 by Sinocelltech Ltd., with 441 participants planned, started 2024-10-10 and due to reach its primary completion in 2027-04-30. Interventions recorded: SCTB41.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sinocelltech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sinocelltech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SCTB41, Sinocelltech.
Shares Sinocelltech and the tag pipeline.
Shares Sinocelltech and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/